Tremography as a Measure of Extrapyramidal Function in Study of the Dopamine Hypothesis

  • Murray Alpert


Although an association between schizophrenia and abnormal movements has long been noted, recent behavioral research in schizophrenia has emphasized cognitive and emotional manifestations almost exclusively. Theoretical work has focused on “mental” phenomena [see, e.g., the behavioral topics considered in Cancro’s reviews of schizophrenia (1971, 1972)], although clinicians recognize certain motor abnormalities as part of the schizophrenic syndrome (Fish, 1967). Movements such as posturing, mannerisms, waxy flexibility, etc., contribute to the establishment of the diagnosis, or to decisions as to the severity of illness.


Extrapyramidal Side Effect Tremor Amplitude Elevated Mood Dysphoric Mood Dopamine Hypothesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alpert, M., and Diamond, F., 1967, Regularity of tremor in extrapyramidal disease, in: Progress in Neuro-Genetics, Vol. I, pp. 040–405, Excerpta Med Intern. Congr. Series #175.Google Scholar
  2. Alpert, M., Lomask, M., and Friedhoff, A. J., 1966, Instrumentation for the recording and predictive analysis of physiological tremor, in: Instrumentation Methods for Predictive Medicine ( T. B. Weber and J. Poyer, eds.), Instrument Society of America, Los Angeles.Google Scholar
  3. Alpert, M., Angrist, B., Diamond, F., and Gershon, S., 1972, Neurohumoral mechanisms mediating the autonomic, CNS, and psychotoxic effects of amphetamines in humans, Presented at the 27th Annual Meeting of the Society of Biological Psychiatry, Texas.Google Scholar
  4. Alpert, M., Diamond, F., Kesselman, M., and Mas, F., 1973, Association between therapeutic and extrapyramidal effects in pharmacotherapy of schizophrenia, Presented at the 28th Annual Meeting of the Society of Biological Psychiatry, Montreal.Google Scholar
  5. Angrist, B., Shopsin, B., and Gershon, S., 1971, Comparative psychotomimetic effects of stereoisomers of amphetamine, Nature 234: 152.PubMedCrossRefGoogle Scholar
  6. Angrist, B., Sathananthan, G., and Gershon, S., 1973, Behavioral effects of L-dopa in schizophrenic patients, Psychopharmacologia 31: 1.PubMedCrossRefGoogle Scholar
  7. Ayd, F., 1961, A survey of drug-induced extrapyramidal reactions, J. Am. Med. Assoc. 175: 1054CrossRefGoogle Scholar
  8. Brimblecombe, R. W., and Pinder, R. M., 1972, Tremors and Tremorgenic Agents, Scientechnica, Bristol. Cancro, R., (ed.), 1971, 1972, Annual Review of the Schizophrenic Syndrome Vols. 1 and 2, Brunner-Mazel, New York.Google Scholar
  9. Carlsson, A., Persson, T., Roos, B. E., and Walinder, 1972, Potentiation of phenothiazines by methyltyrosine in treatment of chronic schizophrenia, J. Neural Transmission 33: 83–90.CrossRefGoogle Scholar
  10. Carlsson, A., Persson, T., Roos, B. E., Walinder, and Skott, A., 1973, Further studies on the mechanisms of antipsychotic action, J. Neural Transmission 34: 125.CrossRefGoogle Scholar
  11. Cole, J. O., and Clyde, D. J., 1961, Extrapyramidal side effects and clinical response to the phenothiazines, Rev. Can. Biol. 20: 565–574.PubMedGoogle Scholar
  12. Davis, J. M., 1965, The efficacy of the tranquilizing and antidepressant drugs, Arch. Gen. Psychiat. 13: 552.PubMedCrossRefGoogle Scholar
  13. Davis, J. M., and Janowsky, D., 1973, Amphetamine and methylphenidate psychoses, in: Frontiers in Catecholamine Research ( E. Usdin and S. H. Snyder, eds.), Pergamon Press, New York.Google Scholar
  14. Duvoisin, R. C., 1967, Cholinergic-anticholinergic antagonism in parkinsonism, Arch. Neurol. 17: 124.PubMedCrossRefGoogle Scholar
  15. Ellinwood, E. H., Jr., 1967, Amphetamine psychosis: I, Description of the individuals and process, J. Nervous Mental Disease 144: 273.CrossRefGoogle Scholar
  16. Ellinwood, E. H., Jr., 1968, Amphetamine psychosis: II, Theoretical implications, J. Neuropsychiat. 4: 45.Google Scholar
  17. Epstein, S., and Coleman, M., 1970, Psychosomat. Med. 32: 113.Google Scholar
  18. Fish, F., 1967, Clinical Psychopathology, John Wright and Sons, Bristol.Google Scholar
  19. Friedhoff, A., and Alpert, M., 1973, A dopaminergic-cholinergic mechanism in the production of psychotic symptoms, Biol. Psychiat. 6: 165.PubMedGoogle Scholar
  20. Friedhoff, A. J., and Van Winkle, E., 1964, Biological O-methylation and schizophrenia, Psychiat. Res. Rep. Am. Psychiat. Assoc. 19: 149.Google Scholar
  21. Gershon, S., Hekimian, J. J., Floyd, A., Jr., and Hollister, L. E., 1967, Methyl-p-tyrosine (AMT) in schizophrenia, Psychopharmacologia 11: 189.PubMedCrossRefGoogle Scholar
  22. Griffith, J. D., Cavanaugh, J. H., and Oates, J. A., 1970, Psychosis induced by the administration of d-amphetamine to human volunteers, in: Psychotomimetic Drugs ( D. H. Efron, ed.), Raven Press, New York.Google Scholar
  23. Himwich, H. E., 1971, Biochemistry, Schizophrenia, and Affective Illnesses Williams and Wilkins, Baltimore.Google Scholar
  24. Hornykiewicz, O., 1966, Dopamine (3-hydroxytyramine) and brain function, Pharmacol. Rev. 18: 925.PubMedGoogle Scholar
  25. Kety, S., 1966, Current biochemical research in schizophrenia, in: Psychopathology of Schizophrenia ( P. H. Hoch and J. Zubin, eds.), Grune and Stratton, New York.Google Scholar
  26. Kety, S., 1970, The hypothetical relationships between amines and mental illness: a cortical snythesis, in: Amines and Schizophrenia ( H. E. Himwich, S. Kety, and J. R. Smythies, eds.), pp. 271–277, Pergamon Press, New York.Google Scholar
  27. Kraeplin, E., 1918, Dementia Praecox E. and S. Livingstone, London.Google Scholar
  28. Miller, R. J., and Hiley, C. R., 1974, Anti-muscaric properties of neuroleptics and drug-induced parkinsonism, Nature 248: 596.PubMedCrossRefGoogle Scholar
  29. Randrup, A., and Munkvad, S., 1966, Role of catecholamines in the amphetamine excitatory response, Nature 211: 540.PubMedCrossRefGoogle Scholar
  30. Randrup, A., and Munkvad, S., 1967, Stereotyped activities produced by amphetamine in several animal species and man, Psychopharmacologia 11: 300.PubMedCrossRefGoogle Scholar
  31. Rubovits, R., and Klawans, H. L., 1972, Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesia, Arch. Gen. Psychiat. 27: 502–507.PubMedCrossRefGoogle Scholar
  32. Smythies, J. R., and Ansun, F., 1970, The biochemistry of psychosis, Scot. Med. J. 15: 34–40.PubMedGoogle Scholar
  33. Snyder, S. H., 1972, Catecholamines in the brain as indicators of amphetamine psychosis, Arch. Gen. Psychiat. 27: 169–179.PubMedCrossRefGoogle Scholar
  34. Snyder, S., Greenberg, D., and Yamarura, H. J., 1974, Antischizophrenic drugs and brain cholinergic receptors, Arch. Gen. Psychiat. 31: 58–61.PubMedCrossRefGoogle Scholar
  35. Stevens, J. R., 1973, An anatomy of schizophrenia, Arch. Gen. Psychiat. 29: 177.PubMedCrossRefGoogle Scholar
  36. Ungerstedt, U., 1971, Stereotaxic mapping of the monoamine pathways in the rat brain, Acta Physiol. Scand. Suppl. 367: 1.PubMedGoogle Scholar
  37. Yardin, P. E., and Discipio, W. J., 1971, Abnormal movements and prognosis in schizophrenia, Am. J. Psychiat. 128: 317–323.Google Scholar
  38. Yaryura-Tobias, J. A., Diamond, B., and Merlis, S., 1970, The action of L-dopa on schizophrenic patients, Current Therap. Res. 12: 528–531.Google Scholar

Copyright information

© Plenum Press, New York 1975

Authors and Affiliations

  • Murray Alpert
    • 1
  1. 1.School of MedicineNew York UniversityNew YorkUSA

Personalised recommendations